Effects of Human Intravenous Immune Globulin on Diarrhea Caused by Shiga-Like Toxin I and Shiga-Like Toxin II in Infant Rabbits

J-STAGE
  • HAVENS Peter L.
    Department of Pediatrics, Medical College of Wisconsin and Children's Hospital of Wisconsin
  • DUNNE W. Michael
    Department of Pathology, Medical College of Wisconsin and Children's Hospital of Wisconsin
  • BURD Eileen M.
    Department of Pediatrics, Medical College of Wisconsin and Children's Hospital of Wisconsin

抄録

Shiga toxin and the related Shiga-like toxins (SLT), produced by Escherichia coli, can cause hemorrhagic colitis and hemolytic uremic syndrome (HUS). Human intravenous immune globulin (HIVIg) blocks the cytotoxicity of some SLTs in vitro. To examine the ability of HIVIg to modify disease caused by Shiga-like toxin I or Shiga-like toxin II (SLT-I or SLT-II), we injected 3-day-old rabbits intraperitoneally with SLT-containing cell-free supernatants from Escherichia coli O157: H7. A subset of rabbits was treated with subcutaneous HIVIg. All rabbits given 104 CD50 of SLT-I developed severe diarrhea, and 5 died. When HIVIg 500mg/kg was given in addition to SLT-I, only 6 of 18 rabbits (33.3%) developed diarrhea (P<0.0001), and 1 died. HIVIg 500mg/kg or 1, 000mg/kg protected against diarrhea when given one hour prior to toxin. HIVIg 1, 000mg/kg was protective when administered one hour after toxin, but not at 6 or 24hr. Seventeen of 18 rabbits given 106 CD50 of SLT-II developed severe diarrhea, and 4 died. In contrast to SLT-I-associated disease, HIVIg had no effect on diarrhea in rabbits given SLT-II. We conclude that HIVIg protects infant rabbits from diarrhea and death caused by by intrapertoneally administered SLT-I, but does not affect the course of SLT-II-associated illness.

収録刊行物

詳細情報 詳細情報について

問題の指摘

ページトップへ